Author: Customer Service

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 05, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded an additional USD 5.4 million of funding to Basilea to continue the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. David Veitch, Chief Executive Officer of Basilea, said:...

PASCAGOULA, Miss., Aug. 04, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) and HD Hyundai Heavy Industries (HHI) are advancing their strategic partnership with a pilot program to implement additional intelligent mechanized welding equipment at HII’s Ingalls Shipbuilding division, expanding Ingalls’ robust existing automation and technology strategy. The pilot is a meaningful step in advancing U.S.-Korea shipbuilding cooperation, as outlined in a 2025 memorandum of understanding (MOU) between the two companies, and underscores HII’s commitment to innovate operations as it delivers ships to the U.S. Navy. “Ingalls operates one of the most advanced automated production lines in the U.S. shipbuilding industrial base,” Ingalls Shipbuilding President Brian Blanchette said. “Investments in technology and automation range from large-scale automated...

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase agreement for a private placement financing with new and existing fundamental investors. The financing is expected to result in aggregate gross proceeds to the Company of approximately $10 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the financing to support...

SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) — Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial public offering of 17,000,000 shares of its common stock at an initial public offering price of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $289.0 million. All shares of common stock to be sold in the offering will be sold by Attovia. In addition, Attovia has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 shares of common stock at the initial public offering price, less underwriting discounts...

TORONTO, Aug. 04, 2026 (GLOBE NEWSWIRE) — McEwen Inc. (NYSE/TSX: MUX) (“McEwen”, “MUX” or the “Company”) invites you to join our Q2 2026 conference call on Thursday, August 6, 2026, at 11:00 a.m. EDT. Management will discuss our financial results and project developments, followed by a question-and-answer session.McEwen Q2 2026 Results Conference CallThursday, August 6, 2026, at 11:00 a.m. EDT Listen to the webcast:Shareholders and other attendees can register here: https://events.q4inc.com/attendee/349025307/guest Ask a question during the live Q&A:Analysts and other participants who wish to ask a question by phone can register here: https://events.q4inc.com/analyst/349025307?pwd=4Vp35oF5An archived replay of the webcast will be available approximately two hours after the conclusion of the live event....

Waratah Capital Advisors confirms it will vote in favour of all six Management Nominees proposed for election as directors at the Company’s annual general and special meeting of shareholders on August 18, 2026 TORONTO, Aug. 04, 2026 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) is pleased to announce that Waratah Capital Advisors Ltd. (together with its affiliates and investment funds managed by it and its affiliates, “Waratah”) has formally withdrawn its requisition for a special meeting of shareholders of the Company (the “Requisition”) and has confirmed to the Company that it will vote in favour of the election of all six Management Nominees proposed for election as directors, and in favour of the other items of business recommended for approval by management, at...

Rocket Lab Awarded $397 Million Contract to Build and Launch Flatellites for U.S. Space Force’s Space-Based Airborne Moving Target Indicator ProgramArtist impression of Rocket Lab Flatellite spacecraft inside a Neutron launch vehicle fairing.LONG BEACH, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today announced it has been awarded a $397 million contract by the United States Space Force under the Space-Based Airborne Moving Target Indicator (SB-AMTI) program. The initiative, led by the Portfolio Acquisition Executive (PAE) for Space-Based Sensing and Targeting (SBST), aims to enhance global security by deploying a resilient space-based system to detect and track airborne threats in real time. Under the contract, Rocket Lab will develop,...